Share-based Payment Arrangement, Expense of MiNK Therapeutics, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
MiNK Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • MiNK Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $621,000, a 30% decline year-over-year.
  • MiNK Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $2,479,000, a 30% decline year-over-year.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $2,842,000, a 26% decline from 2023.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,830,000, a 27% increase from 2022.
  • MiNK Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,027,000, a 73% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

MiNK Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $2,479,000 $621,000 -$262,000 -30% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $2,741,000 $897,000 +$53,000 +6.3% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $2,688,000 $571,000 -$154,000 -21% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $2,842,000 $390,000 -$682,000 -64% 01 Oct 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
Q3 2024 $3,524,000 $883,000 -$56,000 -6% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $3,580,000 $844,000 -$54,000 -6% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $3,634,000 $725,000 -$196,000 -21% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $3,830,000 $1,072,000 +$405,000 +61% 01 Oct 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
Q3 2023 $3,425,000 $939,000 +$166,000 +21% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $3,259,000 $898,000 +$97,000 +12% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $3,162,000 $921,000 +$135,000 +17% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $3,027,000 $667,000 -$305 -0.05% 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $3,027,305 $773,000 +$385,638 +100% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $2,641,667 $801,000 +$393,697 +97% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $2,247,970 $786,000 +$502,970 +178% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $1,745,000 $667,305 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
Q3 2021 $387,362 +$376,608 +3502% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $407,303 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $283,030 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q3 2020 $10,754 01 Jul 2020 30 Sep 2020 10-Q 29 Nov 2021 2021 Q3

MiNK Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $2,842,000 -$988,000 -26% 01 Jan 2024 31 Dec 2024 10-K 18 Mar 2025 2024 FY
2023 $3,830,000 +$803,000 +27% 01 Jan 2023 31 Dec 2023 10-K 18 Mar 2025 2024 FY
2022 $3,027,000 +$1,282,000 +73% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $1,745,000 +$1,657,000 +1883% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023 2022 FY
2020 $88,000 01 Jan 2020 31 Dec 2020 10-K 18 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.